|1.||Maekawa, Ryuji: 4 articles (11/2002 - 01/2002)|
|2.||Yoshioka, Takayuki: 4 articles (11/2002 - 01/2002)|
|3.||Maki, Hideo: 3 articles (09/2005 - 01/2002)|
|4.||Sawada, Takuko Yamada: 2 articles (11/2002 - 01/2002)|
|5.||Hojo, Kanji: 2 articles (11/2002 - 01/2002)|
|6.||Maekawa, R: 2 articles (05/2001 - 01/2000)|
|7.||Yoshioka, T: 2 articles (05/2001 - 01/2000)|
|8.||Wu, Jun-Ben: 1 article (01/2015)|
|9.||Song, De-Kun: 1 article (01/2015)|
|10.||Xu, Huai-Yong: 1 article (01/2015)|
05/01/2001 - "Treatment of pancreatic tumors with MMI-166 caused a significant reduction in the microvessel density from 37.90 +/- 10.18/mm(2) to 16.16 +/- 3.15/mm(2) and a significant increase in apoptotic index from 1.75 +/- 0.41% to 3.96 +/- 0.38%, but there was no significant difference between tumor cell proliferation in the MMI-166-group and the control group. "
09/01/2005 - "MMI-166 dose-dependently inhibited the invasion of cancer cell lines with expressions of MMP-2 and/or MMP-9 in vitro. "
11/01/2002 - "with MMI-166 from 1 day after tumor inoculation. "
04/25/2002 - "Therefore, MMI-166 seems to be useful for tumor dormancy therapy of SCCHN."
04/25/2002 - "These results suggested that orally administered MMI-166 reduced in vivo tumor growth of SCCHN through inhibition of angiogenesis and induction of apoptosis accompanied by the reduction of MMP productions and activities. "
|2.||Neoplasm Metastasis (Metastasis)
05/01/2001 - "MMI-166 significantly reduced the incidence of liver surface metastasis from 66.7% to 20.0%, and it reduced the number of liver surface metastases per animal from 6.17 to 2.00, but this reduction was not significant. "
01/01/2000 - "These results indicate that the selective MMP inhibitor MMI-166 has therapeutic potential as an anti-metastasis agent."
09/01/2005 - "The purpose of this study was to evaluate the effects of MMI-166 on both the growth of the implanted tumor and the lymph node metastasis of the mediastinum and prolonging the life span, using an orthotopic implantation model of the Ma44-3 cancer cell line. "
01/01/2015 - "MMI-166 is a third-generation selective matrix metalloproteinase (MMP) inhibitor that prevents tumor invasion and metastasis by downregulating the activity of MMP-2 and MMP-9. "
09/01/2005 - "These results showed that MMI-166 could possibly inhibit lymph node metastasis and prolong the life span in lung cancer patients."
|3.||Colonic Neoplasms (Colon Cancer)
01/10/2002 - "Conclusively, MMI-166 is a potent antiangiogenic oral agent for a human colon cancer."
01/10/2002 - "Mice implanted a human colon cancer orthotopically received 200 mg/kg of MMI-166 orally for 5 weeks. "
01/10/2002 - "Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166."
06/01/2001 - "In this study, we examined the effects of a new selective MMP inhibitor, MMI-166, on tumor growth, angiogenesis and metastasis in a liver metastatic model of human xenotransplanted colon cancer (TK-4). "
01/01/2002 - "In conclusion, we demonstrated that the anti-metastatic efficacy against C-1H colon cancer and TMK-1 gastric cancer were augmented by the combination therapy of MMI-166, an orally active MMP inhibitor, with CPT-11. "
|4.||Stomach Neoplasms (Stomach Cancer)
|5.||Gastrointestinal Neoplasms (Gastrointestinal Cancer)
|8.||DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)
|2.||Heterologous Transplantation (Xenotransplantation)